WO2006075743A1 - O/wエマルション組成物 - Google Patents
O/wエマルション組成物 Download PDFInfo
- Publication number
- WO2006075743A1 WO2006075743A1 PCT/JP2006/300455 JP2006300455W WO2006075743A1 WO 2006075743 A1 WO2006075743 A1 WO 2006075743A1 JP 2006300455 W JP2006300455 W JP 2006300455W WO 2006075743 A1 WO2006075743 A1 WO 2006075743A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- purified water
- heated
- partially saponified
- emulsion composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 146
- 239000000839 emulsion Substances 0.000 title claims abstract description 51
- 238000007127 saponification reaction Methods 0.000 claims abstract description 42
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 34
- 239000003921 oil Substances 0.000 claims description 116
- 235000019198 oils Nutrition 0.000 claims description 115
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- 239000007788 liquid Substances 0.000 claims description 30
- 229920005862 polyol Polymers 0.000 claims description 19
- 150000003077 polyols Chemical class 0.000 claims description 19
- 239000004094 surface-active agent Substances 0.000 claims description 16
- -1 fatty acid triglycerides Chemical class 0.000 claims description 15
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- 239000008158 vegetable oil Substances 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000006071 cream Substances 0.000 abstract description 42
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract description 20
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract description 19
- 239000006210 lotion Substances 0.000 abstract description 5
- 239000000499 gel Substances 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 239000007921 spray Substances 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 106
- 239000008213 purified water Substances 0.000 description 98
- 239000007864 aqueous solution Substances 0.000 description 75
- 235000019441 ethanol Nutrition 0.000 description 61
- 239000012071 phase Substances 0.000 description 60
- 238000009472 formulation Methods 0.000 description 55
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 50
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 48
- 239000008346 aqueous phase Substances 0.000 description 47
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 43
- 229940043276 diisopropanolamine Drugs 0.000 description 43
- 229920000642 polymer Polymers 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 34
- 150000004667 medium chain fatty acids Chemical class 0.000 description 29
- 238000012360 testing method Methods 0.000 description 27
- 229940058015 1,3-butylene glycol Drugs 0.000 description 25
- 235000019437 butane-1,3-diol Nutrition 0.000 description 25
- 238000003756 stirring Methods 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 17
- 238000002156 mixing Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000000007 visual effect Effects 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 235000019489 Almond oil Nutrition 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 239000008168 almond oil Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229960005150 glycerol Drugs 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 3
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 3
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 3
- MXQXWJVQZHHBJV-UHFFFAOYSA-N 7h-purine-2-carboxylic acid Chemical compound OC(=O)C1=NC=C2N=CNC2=N1 MXQXWJVQZHHBJV-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 3
- OWRMXHRUFYLLQP-UHFFFAOYSA-N [3-[2,3-bis(16-methylheptadecanoyloxy)propoxy]-2-hydroxypropyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)COCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C OWRMXHRUFYLLQP-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229960003657 dexamethasone acetate Drugs 0.000 description 3
- 229940031569 diisopropyl sebacate Drugs 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 3
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 3
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- 239000010466 nut oil Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 229940037001 sodium edetate Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000003871 white petrolatum Substances 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZNWWKYGEXUDHCX-UHFFFAOYSA-N 10-decoxy-10-oxodecanoic acid Chemical compound CCCCCCCCCCOC(=O)CCCCCCCCC(O)=O ZNWWKYGEXUDHCX-UHFFFAOYSA-N 0.000 description 2
- YICVJSOYNBZJAK-UHFFFAOYSA-N 14-methylpentadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C YICVJSOYNBZJAK-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- RKJGFHYCZPZJPE-UHFFFAOYSA-N 2,2-bis(16-methylheptadecanoyloxymethyl)butyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(CC)(COC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C RKJGFHYCZPZJPE-UHFFFAOYSA-N 0.000 description 2
- QOOJEEZYYXGPAO-UHFFFAOYSA-N 2,2-bis(2-ethylhexanoyloxymethyl)butyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(CC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC QOOJEEZYYXGPAO-UHFFFAOYSA-N 0.000 description 2
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 2
- OPJWPPVYCOPDCM-UHFFFAOYSA-N 2-ethylhexyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC OPJWPPVYCOPDCM-UHFFFAOYSA-N 0.000 description 2
- PTPDZZWUOHQSLG-UHFFFAOYSA-N 2-octyldodecyl 2,2-dimethylpropanoate Chemical compound CCCCCCCCCCC(COC(=O)C(C)(C)C)CCCCCCCC PTPDZZWUOHQSLG-UHFFFAOYSA-N 0.000 description 2
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 235000019487 Hazelnut oil Nutrition 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 2
- 240000000912 Macadamia tetraphylla Species 0.000 description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 2
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 229910052614 beryl Inorganic materials 0.000 description 2
- PKVYKIKWKPWIMO-UHFFFAOYSA-N bis(2-butyloctyl) decanedioate Chemical compound CCCCCCC(CCCC)COC(=O)CCCCCCCCC(=O)OCC(CCCC)CCCCCC PKVYKIKWKPWIMO-UHFFFAOYSA-N 0.000 description 2
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229940075510 carbopol 981 Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940074979 cetyl palmitate Drugs 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 2
- 229940031016 ethyl linoleate Drugs 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000008169 grapeseed oil Substances 0.000 description 2
- 239000010468 hazelnut oil Substances 0.000 description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 2
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940078568 isocetyl myristate Drugs 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 229940078812 myristyl myristate Drugs 0.000 description 2
- 229940073665 octyldodecyl myristate Drugs 0.000 description 2
- 229940048862 octyldodecyl neopentanoate Drugs 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 2
- 239000010667 rosehip oil Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229940118594 trimethylolpropane triisostearate Drugs 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- ZNTSHOCZJREHKI-UHFFFAOYSA-N 2-ethylhexanoic acid;4-methyloctane-3,3-diol Chemical compound CCCCC(CC)C(O)=O.CCCCC(C)C(O)(O)CC ZNTSHOCZJREHKI-UHFFFAOYSA-N 0.000 description 1
- QGVQOXWNOSEKGM-UHFFFAOYSA-N 2-hydroxyacetic acid;prop-1-ene Chemical compound CC=C.OCC(O)=O QGVQOXWNOSEKGM-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical group CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- IBWPUTAKVGZXRB-UHFFFAOYSA-N 4-(1,3-benzodioxol-5-yl)butan-2-ylhydrazine Chemical compound NNC(C)CCC1=CC=C2OCOC2=C1 IBWPUTAKVGZXRB-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical class 0.000 description 1
- XIMBJDAVAUWHRB-UHFFFAOYSA-N 6-(3-ethyl-2,4-dimethylpentan-3-yl)oxy-6-oxohexanoic acid Chemical compound CCC(C(C)C)(C(C)C)OC(=O)CCCCC(=O)O XIMBJDAVAUWHRB-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001072282 Limnanthes Species 0.000 description 1
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010073150 Multiple endocrine neoplasia Type 1 Diseases 0.000 description 1
- IEZRNEGTKRQRFV-LFBNJJMOSA-N N-octadecanoyl-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC IEZRNEGTKRQRFV-LFBNJJMOSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- OHMBHFSEKCCCBW-UHFFFAOYSA-N hexane-2,5-diol Chemical compound CC(O)CCC(C)O OHMBHFSEKCCCBW-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960000570 luliconazole Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 229960005040 miconazole nitrate Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- VWOIKFDZQQLJBJ-DTQAZKPQSA-N neticonazole Chemical compound CCCCCOC1=CC=CC=C1\C(=C/SC)N1C=NC=C1 VWOIKFDZQQLJBJ-DTQAZKPQSA-N 0.000 description 1
- 229950010757 neticonazole Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- NCYDRNOBBHFJHE-UHFFFAOYSA-N propane-1,2-diol;prop-1-ene Chemical compound CC=C.CC(O)CO NCYDRNOBBHFJHE-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 125000001444 retinoyl group Chemical group O=C([*])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 1
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristoyl-sn-glycerol Natural products CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037366 wrinkle cream Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8129—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to an oZw emulsion composition that is safe and less irritating when used on the skin, can be stored stably for a long period of time, and has an excellent usability.
- emulsified compositions that are used directly on the skin can be one of the causes of surfactants irritating the skin (Non-patent Document 1). And 2).
- an emulsified composition using a modified polyvinyl alcohol obtained by saponifying a copolymer of olefin sulfonic acid alkali salt and butyl acetate (see Patent Document 1) or alkyl methacrylate methacrylate.
- Patent Document 2 An emulsified composition using an alkyl-modified carboxyvinyl polymer such as a copolymer is known.
- a surfactant is also added to the above cream, and a stable partially saponified polyvinyl alcohol and a carboxybutylic polymer, even though no surfactant is added.
- An emulsified composition that can also be used is obtained.
- Non-Patent Literature 1 Tamie Suzuki et al., Hichikyokyo Journal, 51, 177-183 (2004)
- Non-Patent Document 2 Kotobuki Sumi et al., Skin, 33 (11), 31-38 (1991)
- Patent Document 1 Japanese Patent Laid-Open No. 51-3383
- Patent Document 2 JP 09-19631 A
- Patent Document 3 Japanese Patent Laid-Open No. 2001-39851
- the present invention uses a partially saponified polybulal alcohol and a carboxybulum polymer, and can be stored stably for a long period of time without substantially adding a surfactant, and has excellent usability.
- An object is to provide an emulsion composition.
- a saponification degree of 70 to 96 mol% of partially saponified polybulal alcohol and carboxybule polymer is 40 wt% or less based on the total amount of the composition.
- a specific oil component and adjusting the pH to 3.5 to 8.5 it can be safely stored with little irritation when used on the skin, can be stored stably for a long period of time, and has a light extension.
- the present inventors have found that an OZW emulsion composition having an excellent usability can be obtained, and have completed the present invention.
- the present invention is as follows.
- OZw emulsion composition characterized by containing.
- the polar liquid oil is a vegetable oil mainly composed of fatty acid triglycerides as described in (3) above.
- the present invention has succeeded in obtaining an oZw emulsion composition that can be stably stored for a long period of time and has high safety with less irritation when used on the skin. Furthermore, according to the present invention, it is possible to obtain an oZw emulsion composition that has a light extension and maintains an excellent feeling after use.
- the "partially saponified polyvinyl alcohol” in the present invention means a partially saponified polyvinyl acetate obtained by polymerizing vinyl acetate.
- the viscosity of a 4% aqueous solution is 8 to 5.
- OmPa's have several types of different forces such as OmPa's. If a saponification degree of 70 to 96 mol%, which is generally used regardless of viscosity, is used, a stable OZW emulsion can be produced.
- partially saponified polybulal alcohol having a saponification degree of 78 to 96 mol% is preferred, and in particular, partially saponified polybulal alcohol having a saponification degree of 85 to 90 mol% is preferred.
- Polybulol alcohol having a degree of saponification of 97 mol% or more, generally called fully saponified polybulal alcohol, is distinguished from partially saponified polybulal alcohol in the present invention.
- the blending amount of the partially saponified polybulal alcohol is 0.1 to 4.0% by mass, and preferably 0.2 to 3.0% by mass with respect to the total amount of the composition.
- the amount of partially saponified polyvinyl alcohol can be adjusted as appropriate according to other ingredients and purpose of use. For example, when it is used as an external cream or lotion for skin, it is 0.5% of the total amount of the preparation. It is preferable to blend so as to be ⁇ 2.0% by mass.
- the "carboxyvinyl polymer” in the present invention means a copolymer of acrylic acid, for example, a 0.5% aqueous solution having a viscosity of 00000 to 10,000 mPa's, 40,000 to 60,000 mPa's. In this invention, it can be properly used depending on the purpose of use. For example, in the case of an external cream for skin, it is preferable to mainly use a low-viscosity type for a lotion preparation that preferably uses a high-viscosity type.
- the blending amount of the carboxyvinyl polymer is 0.1 to 3.0% by mass with respect to the total amount of the composition, and preferably 0.3 to 2.0% by mass in terms of the formulation. O ZW emulsion with good stability can be obtained.
- the blending amount of the oil component is 40 wt% or less with respect to the total amount of the composition, and 60 wt% or more of the oil component is liquid oil. If the oil component exceeds 40 wt% with respect to the total amount of the composition, the oil component separates and emulsion cannot be prepared. Furthermore, when the ratio force of the liquid oil in the oil component is less than S60 wt%, the properties and stability deteriorate. In terms of formulation, the oil component is more preferably 35 wt% or less based on the total amount of the composition.
- the “oil component” in the present invention means a deviation of liquid oil, solid fat, and a mixture thereof, and is preferably liquid oil.
- “Liquid oil” means both non-polar and polar oils that are liquid at 25 ° C.
- the liquid oil is preferably a polar liquid oil.
- the polar liquid oil is preferably a power that is a synthetic oil having an IOB value (Inorganic Organic Balance value) of 0.1 or more, or a vegetable oil mainly composed of fatty acid triglycerides.
- the IOB value here is calculated based on [Yoshio Koda, “Basic Concept and Application of Organic Concepts”, Sankyo Publishing (1984)]. It is a numerical value determined by the value.
- the oil component includes, for example, liquid paraffin and synthetic squalane as nonpolar liquid oil
- examples of polar liquid oil include medium chain fatty acid triglyceride, octyldodecyl myristate, cetyl isooctanoate, Isopropyl myristate, diglyceryl triisostearate, glyceryl tri (force pril Z force purinate), glyceryl tri-2-ethylhexylate, diisopropyl sebacate, tri-2-ethylhexyl citrate, diisopropylpropyl adipate, mono force Propylene glycol prillate, decyl sebacate, 2 monohexyldecyl isostearate, isopropyl palmitate, isopropyl linoleate, ethyl linoleate, triethylhexanoin, propylene glycol dicaprylate
- the oil component is particularly preferably cetyl isooctanoate, isopropyl myristate, diglyceryl triisostearate, glyceryl tri (force prill Z force purinate), glyceryl tri-2-ethyl hexate, diisopropyl sebacate, triacetate.
- oil components may be used alone or in combination of two or more.
- the OZW emulsion of the present invention preferably has a pH adjusted to 3.5 to 8.5. If the pH value is less than 3.5, the emulsion stability becomes poor and the desired OZW emulsion cannot be obtained. In addition, when the OZW emulsion of the present invention is used for skin, there is a concern that irritation to the skin may occur when the pH exceeds 8.5, and it is not suitable for skin. From the viewpoint of formulation, it is more preferable to adjust the pH to 4.5 to 8.0.
- the pH adjuster is not particularly limited, and a basic compound blended in ordinary pharmaceuticals and cosmetics can be used.
- a basic compound blended in ordinary pharmaceuticals and cosmetics can be used.
- diisopropanolamine, triisopropanolamine, sodium hydroxide, monoethanolamine, diethanolamine, triethanolamine, triethylamine, potassium hydroxide and sodium citrate can be mentioned.
- these pH regulators can be used alone or in combination of two or more.
- the "external composition" in the present invention is a dosage form generally used when ozw emulsion is applied to the skin, mucous membrane, eyes, etc., such as cream, lotion, ointment, gel, spray, etc. And can be used for pharmaceuticals, cosmetics, quasi drugs and the like.
- the excellent feeling of use of the present emulsion can be maintained.
- the polyol that can be used in the present invention is not particularly limited, and for example, 1,3-butylene glycol, propylene glycol, dipropylene glycol, glycerin, and polyethylene glycol can be used.
- 1,3-butylene glycol, propylene glycol, dipropylene glycol, glycerin, and polyethylene glycol can be used.
- one or two or more of these polyols can be blended.
- substantially free of surfactant means that the surfactant is blended, or an amount that does not sufficiently exhibit the surfactant effect.
- the surfactant is a compound having a hydrophilic group and a hydrophobic group, which usually dissolves in water and greatly changes properties such as surface tension, and at the same time forms aggregates such as micelles in water. Means.
- the OZW emulsion of the present invention can be manufactured according to a general manufacturing method of emulsion.
- carboxybule polymer is dispersed in purified water, heated and dissolved in partially purified polyvinyl alcohol, which is heated separately, and the two aqueous solutions are combined to form an aqueous phase.
- the oil component a polyol can be appropriately added if necessary
- the target OZW emulsion can be obtained by adding the oil phase to the aqueous phase, stirring further until it becomes homogeneous by adding purified water, and then cooling to room temperature while stirring.
- the pH adjuster is dissolved in an appropriate amount in the oil phase or finally purified water.
- the OZW emulsion prepared in this way can be stored stably for a long period of time, and since it is not necessary to add a surfactant, the emulsion is less irritating when used on the skin. be able to. In addition, the excellent feeling of use lasts even after application with light extension.
- the OZW emulsion of the present invention can be added with various active ingredients and various base ingredients that can be contained in pharmaceuticals, quasi-drugs, and cosmetics within a range that does not impair the intended effect.
- the active ingredient includes, for example, anti-inflammatory agents (indomethacin, piroxicam, diclofenac sodium, ferbinac, hydrocortisone acetate, dexamethasone acetate, etc.), analgesics, antihistamines (diphenhydramine, chlorfelamine maleate, isothipentyl hydrochloride, etc.) , Local anesthetics (Lido In, Pro In, Jib In, Lidocaine Hydrochloride, Pro In Inn Hydrochloride, Jib In Inn Hydrochloride, etc.), Tissue Repair Agent, Antipruritic Agent (Crotamiton etc.), Urea, Moisturizer (Hyaluronic Acid) , Ceramides, etc.), refreshing agents (menthol, camphor, etc.), vitamins and their derivatives (vitamin k, vitamin B, vitamin C, vitamin E, etc.), vasoconstrictors (tetrahydrozoline hydrochloride, furefref
- the base component examples include solubilizers such as lower alcohols (ethanol, isopropanol, etc.), hydrocarbons, wax components, antioxidants (dibutylhydroxytoluene, etc.), emulsion stabilizers, gelling agents.
- solubilizers such as lower alcohols (ethanol, isopropanol, etc.), hydrocarbons, wax components, antioxidants (dibutylhydroxytoluene, etc.), emulsion stabilizers, gelling agents.
- Carbopol 980 manufactured by Noveon is used as the carboxybule polymer
- Panacet 810 manufactured by Nippon Oil & Fats is used as the medium chain fatty acid triglyceride
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Canoleboxyvininole polymer 0.8 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) 1. 2w / w%
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polybulal alcohol (saponification degree 86.5-89.0 mol%) 0.8 w / w%
- 0.5 g of carboxyvinyl polymer is dispersed in 25 g of purified water and heated to about 70 ° C to dissolve in water. A liquid was obtained. Further, 0.8 g of partially saponified polybulal alcohol was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 10 g of isopropyl myristate and 2 g of stearyl alcohol was heated to about 70 ° C. to obtain an oil phase.
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) 1. 2w / w%
- Canoleboxyvininole polymer 0. lw / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Carbopol 980 * Noveon viscosity 40000-60000mPa ⁇ s (0.5%)
- 0.3 g of the two carboxybule polymers in total was dispersed in 25 g of purified water and heated to about 70 ° C to obtain an aqueous solution. Further, partially saponified polybulal alcohol lg was dissolved in 25 g of purified water heated to 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 10 g of medium chain fatty acid triglyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C, and diisopropanolamine (appropriate amount) was dissolved therein to obtain an oil phase. Add oil phase to water phase Further, the remaining purified water was added and stirred until uniform, and then cooled to room temperature with stirring to obtain a lotion agent.
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) 1. 2w / w%
- 0.6 g of carboxyvinyl polymer was dispersed in 30 g of purified water and heated to about 70 ° C to obtain an aqueous solution. Further, 1.2 g of partially saponified polybulal alcohol was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 12 g of medium-chain fatty acid triglyceride and lg of liquid paraffin was heated to about 70 ° C, and this was added to retinoyl normitate 2000001.
- Lidocaine hydrochloride lw / w%
- Canoleboxyvininole polymer 0.75 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- 0.5 g of carboxyvinyl polymer was dispersed in 25 g of purified water and heated to about 70 ° C to obtain an aqueous solution. Further, partially saponified polybulal alcohol lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 13 g of medium chain fatty acid triglyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C, and 0.5 g of dibu force-in and diisopropanolamine (appropriate amount) were dissolved therein to dissolve the oil phase. did. The oil phase was added to the aqueous phase, the remaining purified water was further added, and the mixture was stirred until uniform, and then cooled to room temperature with stirring to obtain a cream.
- Canoleboxyvininole polymer 0.5 w / w% Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- 0.5 g of carboxyvinyl polymer was dispersed in 25 g of purified water and heated to about 70 ° C to obtain an aqueous solution. Further, partially saponified polybulal alcohol lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 13 g of medium chain fatty acid triglyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C., and indomethacin lg and diisopropanolamine (appropriate amount) were dissolved therein to obtain an oil phase. The oil phase was added to the aqueous phase, the remaining purified water was further added, and the mixture was stirred until uniform, and then cooled to room temperature with stirring to obtain a cream.
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Canoleboxyvininole polymer 0.75 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Carboxyvinyl polymer (0.75 g) was dispersed in purified water (25 g) and heated to about 70 ° C. to obtain an aqueous solution. Further, partially saponified polybulal alcohol lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately medium chain fatty acid tri A mixture of 13 g of glyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C., and 1 g of hydrochloric acid and diisopropanolamine (appropriate amount) were dissolved therein to obtain an oil phase. The oil phase was added to the aqueous phase, the remaining purified water was further added, and the mixture was stirred until uniform, and then cooled to room temperature with stirring to obtain a cream.
- Canoleboxyvininole polymer 0.8 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- 0.5 g of carboxyvinyl polymer was dispersed in 25 g of purified water and heated to about 70 ° C to obtain an aqueous solution. Further, partially saponified polybulal alcohol lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 13 g of medium chain fatty acid triglyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C., and disoprono-V-lamine (appropriate amount) was dissolved therein to obtain an oil phase. The oil phase was added to the aqueous phase, and further, 0. Olg of sodium hyaluronate was dissolved in the remaining purified water, stirred until uniform, and then cooled to room temperature with stirring to obtain a cream.
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- 0.5 g of carboxyvinyl polymer was dispersed in 25 g of purified water and heated to about 70 ° C to obtain an aqueous solution. Further, partially saponified polybulal alcohol lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 10 g of medium-chain fatty acid triglyceride and 10 g of propylene glycol monoplyrate was heated to about 70 ° C, and N-stearoylphytosphingosine 0.1 g was dissolved in this to obtain an oil phase.
- Test Example 1 (Prototype Test 1: Carboxybule Polymer Change. Partially Saponified Polyvinyl Alcohol Change Prototype Test)
- Carboxyvinyl polymer (0.5 g) was dispersed in purified water (25 g) and heated to about 70 ° C. to obtain an aqueous solution. Further, partially saponified polybulal alcohol (saponification degree: 86.5 to 89.0 mol%) lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 13 g of medium chain fatty acid triglyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C., and diisopropanolamine (appropriate amount) was dissolved therein to obtain an oil phase. The oil phase was added to the aqueous phase, the remaining purified water was further added, and the mixture was stirred until uniform, and then stirred to cool to room temperature to obtain a cream. This was the basic prescription. The pH was adjusted to 5-7.
- Partially saponified polyvinyl alcohol (saponification degree: 86.5 to 89.0 mol%) modified formulation
- the partially saponified polybulal alcohol in the above basic formulation is sodium carboxymethylcellulose, hydrophobized hydroxypropylmethylcellulose, hydroxypropyl, respectively.
- the modified formulation replaced with cellulose, hydroxyethyl cellulose, sodium alginate or polybulal alcohol (saponification degree 97.0 mol% or more) was used as a cream formulation in the same manner as the above basic formulation.
- modified formulations excluding partially saponified polyvinyl alcohol and carboxyvinyl polymer were prepared in the same manner as the above basic formulation.
- Test Example 2 (Prototype Test 2: Oil Component Change Prototype Test)
- Carboxyvinyl polymer (0.5 g) was dispersed in purified water (25 g) and heated to about 70 ° C. to obtain an aqueous solution. Further, partially saponified polybulal alcohol (saponification degree: 86.5 to 89.0 mol%) lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. Combine two aqueous solutions Phased. Separately, a mixture of 13 g of medium chain fatty acid triglyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C., and diisopropanolamine (appropriate amount) was dissolved to obtain an oil phase. The oil phase was added to the aqueous phase, the remaining purified water was further added, and the mixture was stirred until uniform, and then cooled to room temperature with stirring to obtain a cream. This was the basic prescription. The pH was adjusted to 5-7.
- the medium chain fatty acid triglycerides in the above basic formula are paraffin, white petrolatum (semi-solid), liquid paraffin, synthetic squalane, cetyl palmitate, myristyl myristate, beryl alcohol, cetanol, batyl alcohol, octyldodecyl myristate, Cetyl isooctanoate, isopropyl myristate, diglyceryl triisostearate, glyceryl tri (force prill Z force purinate), glyceryl tri-2-ethylhexylate, diisopropyl sebacate, tri-2-ethylhexyl citrate, adipic acid
- the same procedure as in the above basic formula was performed for the formulation replaced with diisopropyl, propylene glycol monocaprylate, olive oil, almond oil, or castor oil, to obtain a cream.
- the extraction formulation could not prepare an emulsion composition.
- Test Example 3 (Prototype Test 3: Change of pH Regulator ⁇ Polyol Change Trial Test)
- Carboxyvinyl polymer (0.5 g) was dispersed in purified water (25 g) and heated to about 70 ° C. to obtain an aqueous solution. Further, partially saponified polybulal alcohol (saponification degree: 86.5 to 89.0 mol%) lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 13 g of medium chain fatty acid triglyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C., and diisopropanolamine (appropriate amount) was dissolved therein to obtain an oil phase. The oil phase was added to the aqueous phase, the remaining purified water was further added, and the mixture was stirred until uniform, and then stirred to cool to room temperature to obtain a cream. This was the basic prescription. The pH was adjusted to 5-7.
- Test example 4 (prototype test 4: blending amount change test)
- Carboxyvinyl polymer (0.5 g) was dispersed in purified water (25 g) and heated to about 70 ° C. to obtain an aqueous solution. Further, partially saponified polybulal alcohol (saponification degree: 86.5 to 89.0 mol%) lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 13 g of medium chain fatty acid triglyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C., and diisopropanolamine (appropriate amount) was dissolved therein to obtain an oil phase.
- the oil phase was added to the aqueous phase, the remaining purified water was further added, and the mixture was stirred until uniform, and then stirred to cool to room temperature to obtain a cream.
- Partially saponified polyvinyl alcohol (saponification degree 86.5 to 89.0 mol%) blending amount change test Partially saponified polyvinyl alcohol (saponification degree 86.5 to 89.0 mol%) in the above basic formulation was used as a cream.
- the modified formulation of the carboxybule polymer content in the basic formulation was made into a cream by the same operation as the basic formulation.
- the modified formulation for changing the amount of oil component in the basic formulation was treated in the same manner as the basic formulation to obtain a cream.
- Carboxyvinyl polymer (0.5 g) was dispersed in purified water (25 g) and heated to about 70 ° C. to obtain an aqueous solution. Further, partially saponified polybulal alcohol (saponification degree: 86.5 89.0 mol%) lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 13 g of medium chain fatty acid triglyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C., and diisopropanolamine (appropriate amount) was dissolved therein to obtain an oil phase. The oil phase was added to the aqueous phase, the remaining purified water was further added, and the mixture was stirred until uniform, and then cooled to room temperature with stirring force S to obtain a cream. This was the basic prescription.
- the 65 ° CZ2W term confirmed the properties after 65 ° C2W.
- a circle indicates that there was no change immediately after preparation.
- Test Example 6 Liquid Oil Content Change Test for Total Oil Content
- Carboxyvinyl polymer (0.5 g) was dispersed in purified water (25 g) and heated to about 70 ° C. to obtain an aqueous solution. Further, partially saponified polybulal alcohol (saponification degree: 86.5 to 89.0 mol%) lg was dissolved in 25 g of purified water heated to about 70 ° C. to obtain an aqueous solution. The two aqueous solutions were combined into an aqueous phase. Separately, a mixture of 13 g of medium chain fatty acid triglyceride and 10 g of 1,3-butylene glycol was heated to about 70 ° C., and diisopropanolamine (appropriate amount) was dissolved therein to obtain an oil phase. The oil phase was added to the aqueous phase, the remaining purified water was further added, and the mixture was stirred until uniform, and then stirred to cool to room temperature to obtain a cream. This was the basic prescription. The pH was adjusted to 5-7.
- the 65 ° CZ2W term confirmed the properties after 65 ° C2W. A circle indicates that there was no change immediately after preparation.
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Canoleboxyvininole polymer 0.5 w / w% Partially saponified polybulal alcohol (saponification degree 86.5-89.0mol%) lw / w% 1,3-butyleneglycolanol 10w / w%
- Test Example 8 (Usability test)
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polyvinyl alcohol (saponification degree 86.5-89.0mol%) lw / w% propylene glycolate 10w / w%
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polybulal alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- prescription example 5 partially saponified polyvinyl alcohol prescription
- prescription example 4 surfactant prescription
- Canoleboxyvininole polymer 0.5 w / w%
- Partially saponified polyvinyl alcohol (degree of saponification 86.5-89.0mol%) lw / w%
- Carboxybule polymer 0.5 w / w%
- the present invention can be stored stably for a long time, and when used on the skin A highly safe oZw emulsion composition with less irritation can be obtained. Furthermore, according to the present invention, it is possible to obtain an oZw emulsion composition that maintains an excellent feeling after use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06711736A EP1847243A1 (en) | 2005-01-17 | 2006-01-16 | O/w emulsion composition |
JP2006553013A JP5141017B2 (ja) | 2005-01-17 | 2006-01-16 | O/wエマルション組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-008508 | 2005-01-17 | ||
JP2005008508 | 2005-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006075743A1 true WO2006075743A1 (ja) | 2006-07-20 |
Family
ID=36677763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/300455 WO2006075743A1 (ja) | 2005-01-17 | 2006-01-16 | O/wエマルション組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080146678A1 (ja) |
EP (1) | EP1847243A1 (ja) |
JP (1) | JP5141017B2 (ja) |
KR (1) | KR20070098921A (ja) |
CN (1) | CN101106969A (ja) |
WO (1) | WO2006075743A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012011192A1 (ja) * | 2010-07-23 | 2012-01-26 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
WO2018092835A1 (ja) * | 2016-11-17 | 2018-05-24 | 千寿製薬株式会社 | 乳剤点眼液 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2901124B1 (fr) * | 2006-05-17 | 2008-06-27 | Oreal | Emulsion huile dans eau fine |
JP7576541B2 (ja) * | 2019-06-28 | 2024-10-31 | ライオン株式会社 | 水中油型クリーム剤の製造方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11180823A (ja) * | 1997-12-22 | 1999-07-06 | Shiseido Co Ltd | 水中油型乳化化粧料 |
JP2000169355A (ja) * | 1998-12-03 | 2000-06-20 | Shiseido Co Ltd | 乳化型ゴマージュ化粧料 |
JP2001039851A (ja) * | 1999-07-28 | 2001-02-13 | Shiseido Co Ltd | 目元用マッサージ化粧料 |
-
2006
- 2006-01-16 KR KR1020077018748A patent/KR20070098921A/ko not_active Application Discontinuation
- 2006-01-16 JP JP2006553013A patent/JP5141017B2/ja not_active Expired - Fee Related
- 2006-01-16 EP EP06711736A patent/EP1847243A1/en not_active Withdrawn
- 2006-01-16 CN CNA2006800024635A patent/CN101106969A/zh active Pending
- 2006-01-16 US US11/795,294 patent/US20080146678A1/en not_active Abandoned
- 2006-01-16 WO PCT/JP2006/300455 patent/WO2006075743A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11180823A (ja) * | 1997-12-22 | 1999-07-06 | Shiseido Co Ltd | 水中油型乳化化粧料 |
JP2000169355A (ja) * | 1998-12-03 | 2000-06-20 | Shiseido Co Ltd | 乳化型ゴマージュ化粧料 |
JP2001039851A (ja) * | 1999-07-28 | 2001-02-13 | Shiseido Co Ltd | 目元用マッサージ化粧料 |
Non-Patent Citations (2)
Title |
---|
SUZUKI T. ET AL.: "Nonion-sei Kasseizai no Shigekisei Hyoka", JOURNAL OF THE JAPANESE SOCIETY FOR CUTANEOUS HEALTH, vol. 26, no. 2, 2004, pages 177 - 183, XP002999597 * |
TATSUMI T. ET AL.: "Keshohin Genryo ni Taisuru Morumotto Hifu Shigekisei Shiken to Hito Tenpu Shiken no Hikaku", HIFU, vol. 33, no. 11, 1991, pages 31 - 38, XP002999598 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012011192A1 (ja) * | 2010-07-23 | 2012-01-26 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
WO2018092835A1 (ja) * | 2016-11-17 | 2018-05-24 | 千寿製薬株式会社 | 乳剤点眼液 |
CN109963556A (zh) * | 2016-11-17 | 2019-07-02 | 千寿制药株式会社 | 乳剂滴眼液 |
JPWO2018092835A1 (ja) * | 2016-11-17 | 2019-10-17 | 千寿製薬株式会社 | 乳剤点眼液 |
JP7044714B2 (ja) | 2016-11-17 | 2022-03-30 | 千寿製薬株式会社 | 乳剤点眼液 |
US11439589B2 (en) | 2016-11-17 | 2022-09-13 | Senju Pharmaceutical Co., Ltd. | Emulsion eyedrops |
Also Published As
Publication number | Publication date |
---|---|
JP5141017B2 (ja) | 2013-02-13 |
JPWO2006075743A1 (ja) | 2008-06-12 |
CN101106969A (zh) | 2008-01-16 |
US20080146678A1 (en) | 2008-06-19 |
KR20070098921A (ko) | 2007-10-05 |
EP1847243A1 (en) | 2007-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007039974A1 (ja) | 乳剤性ローション剤 | |
JP2013513558A (ja) | 乳化剤を含まない、ポリマーで安定化された泡沫製剤 | |
WO2019014380A1 (en) | PLATFORMS FOR TOPICAL ADMINISTRATION OF MEDICAMENTS AND METHODS OF PREPARATION THEREOF | |
JP2004513958A (ja) | クリーム状のパーマネント泡または安定した発泡クリームの形態である化粧用または皮膚科学用薬剤 | |
JP2007523138A (ja) | スキンケア組成物 | |
MX2011005082A (es) | Composicion para el cuidado personal conteniendo un volatil y un alcohol de terpeno. | |
EP2598207A2 (en) | Surfactant-free oil-in-water type emulsion, process for preparation and uses thereof | |
JP2008106043A (ja) | 水中油型乳化化粧料 | |
US20040018250A1 (en) | Methods for preparing high pressure/high shear dispersions containing waxes and other semi-solids and oils | |
WO2001070271A2 (en) | Acid-stable base compositions for preparing surfactant free topical compositions | |
WO2001070270A2 (en) | Base compositions for preparing surfactant free topical compositions | |
JP5141017B2 (ja) | O/wエマルション組成物 | |
JP5662794B2 (ja) | 油中水型乳化組成物 | |
JP5066850B2 (ja) | O/w型エマルション組成物 | |
WO2002004004A1 (en) | Methods for preparing high pressure/high shear dispersions containing waxes and other semi-solidds and oils | |
JP5061521B2 (ja) | O/w型エマルション組成物 | |
JP5056137B2 (ja) | 油中アルコール型エマルション組成物 | |
JP6850599B2 (ja) | 水中油型乳化組成物および皮膚外用剤 | |
JP5061519B2 (ja) | 抗真菌剤含有o/wエマルション組成物 | |
JP2000327516A (ja) | ゲル状皮膚外用組成物 | |
JP2017530166A (ja) | 分散液中の化粧品および/または医薬組成物、皮膚を整えるための組成物の製造方法および使用方法 | |
JP5061518B2 (ja) | アモロルフィン含有o/wエマルション組成物 | |
JP5359171B2 (ja) | 水中油中アルコール型エマルション組成物 | |
JP3670298B2 (ja) | スルホニウム化合物含有皮膚外用剤 | |
JP7500193B2 (ja) | 乳化組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006553013 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680002463.5 Country of ref document: CN Ref document number: 12007501540 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5871/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006711736 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077018748 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2006711736 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11795294 Country of ref document: US |